Prognostic Relationship Between the ABO Blood Groups and Metastatic Gastric Cancer.
abo blood groups
advanced gastric cancer
histopatology
prognosis
tumor location
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
accepted:
10
02
2023
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
16
2
2023
Statut:
epublish
Résumé
Gastric cancer is one of the most common malignant tumors of the digestive system and has a poor prognosis. Since recurrence and distant metastasis are common in gastric cancer, it is important to use practical and reliable prognostic parameters. In this study, the prognostic relationship between the ABO blood groups and metastatic gastric cancer was investigated. Data were collected by retrospectively scanning the files of 225 patients who were followed up with the diagnosis of metastatic gastric cancer in 2010-2022. The patients' demographic data (age, gender), tumor histopathology, tumor location, and ABO and Rh blood groups were evaluated. Of the patients, 138 (61.3%) were male and 87 (38.7%) were female. According to the distribution of the ABO system, blood group A was present in 109 (48.4%) patients, B in 33 (14.7%), AB in 20 (8.9%), and O in 63 (28%). Signet ring cell carcinoma, antrum tumor localization, and distant metastasis were more common in blood groups A and O. According to both the univariate and multivariate analyses, overall survival (OS) was statistically worse in patients with signet ring cell carcinoma and peritoneal metastasis (p < 0.05). The OS rate was the worst in blood group A and best in blood groups AB and B. In this study, blood group A presented as both a risk factor and a poor prognostic factor in the development of metastatic gastric cancer. In addition, signet ring cell histopathology and presence of metastasis were found to be more common in patients with blood group A and associated with a poor prognosis. Blood groups are inexpensive, easily available, and reliable parameters that can provide an idea about both prognosis and survival in gastric cancer. Therefore, they can serve as a guide for clinicians in the follow-up and evaluation of the prognosis of these patients.
Identifiants
pubmed: 36788998
doi: 10.7759/cureus.34837
pmc: PMC9914799
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e34837Informations de copyright
Copyright © 2023, Tuncel et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Med. 2015 Jan 16;13:7
pubmed: 25592962
Br J Cancer. 2014 Jul 8;111(1):174-80
pubmed: 24901236
J Surg Res. 2016 Mar;201(1):188-95
pubmed: 26850201
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gastric Cancer. 2013 Apr;16(2):254-60
pubmed: 22865192
Tumour Biol. 2014 Jul;35(7):7201-8
pubmed: 24771222
Scand J Surg. 2017 Sep;106(3):235-240
pubmed: 28376652
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1665-72
pubmed: 21680535
Cancer Res. 2010 Feb 1;70(3):1015-23
pubmed: 20103627
Am J Epidemiol. 2010 Dec 1;172(11):1280-5
pubmed: 20937632
EClinicalMedicine. 2022 Apr 21;47:101404
pubmed: 35497064
Int J Epidemiol. 2000 Jun;29(3):405-7
pubmed: 10869310
Int J Mol Sci. 2012 Oct 17;13(10):13308-21
pubmed: 23202954
Scand J Surg. 2020 Dec;109(4):309-313
pubmed: 31282314
J Surg Oncol. 2015 Jul;112(1):31-7
pubmed: 26175203
Nat Genet. 2009 Sep;41(9):986-90
pubmed: 19648918
Gut. 2020 May;69(5):823-829
pubmed: 32001553
Eur J Cancer. 2010 Dec;46(18):3345-50
pubmed: 20833034
Br Med J. 1953 Apr 11;1(4814):799-801
pubmed: 13032504
Thromb Res. 2013 Apr;131(4):290-2
pubmed: 23394808
Int J Cancer. 1998 Apr 13;76(2):284-9
pubmed: 9537592
Cancer Res Treat. 2011 Mar;43(1):1-11
pubmed: 21509157